• Wed, September 7, 2022
  • Thu, September 8, 2022

Serge Belanger Initiated (ARQT) at Strong Buy and Held Target at $46 on, Sep 7th, 2022

Serge Belanger of Needham, Initiated "Arcutis Biotherapeutics, Inc." (ARQT) at Strong Buy and Held Target at $46 on, Sep 7th, 2022.

Serge has made no other calls on ARQT in the last 4 months.



There are 3 other peers that have a rating on ARQT. Out of the 3 peers that are also analyzing ARQT, 0 agree with Serge's Rating of Hold.



These are the ratings of the 3 analyists that currently disagree with Serge


  • Jonathan Block of "Goldman Sachs" Maintained at Strong Buy with Increased Target to $50 on, Tuesday, August 2nd, 2022
  • Vikram Purohit of "Morgan Stanley" Maintained at Buy with Increased Target to $45 on, Tuesday, August 2nd, 2022
  • David Lebowitz of "Morgan Stanley" Maintained at Buy with Increased Target to $39 on, Tuesday, June 7th, 2022

Like: 👍